Israeli AI Platform To Aid IVF Launches In Norway Fertility Clinics

An Israeli artificial intelligence (AI) startup that helps women with in-vitro fertilization (IVF) cycles has announced a successful launch of its technology through one of Norway’s largest private networks of fertility clinics. 

Fairtility develops products through a unique technology called CHLOE (Cultivating Life Through Optimal Embryos), which uses AI to assess the viability of a woman’s embryos throughout her IVF cycle, a medical procedure in which the egg is fertilized outside of the body. 

One of their tools is CHLOE EQ, an AI-powered workspace that helps IVF lab assistants and patients throughout the process, including producing automated annotations about egg development, assess the fertilization progress and track embryo growth. 

This process creates transparency throughout the IVF cycle, and helps patients in understanding the reproductive potential of their oocytes (the ovary cells that are able to turn into eggs).

“CHLOE technology is bringing standardization to the subjective and differentiated decision-making that takes place in embryology labs, where protocols and equipment may differ from lab to lab, and with embryologists having varying levels of experience,” said Eran Eshed, CEO and co-founder of Fairtility. 

Norwegian-based fertility clinic network Klinikk Hausken – part of Medicover, a multinational hospital chain in Europe and India  – tested CHLOE EQ technology in two of its embryology labs before introducing it into their IVF clinics. 

“We selected CHLOE EQ for its unmatched ability to provide quantifiable biological data on embryo development in language that our embryologists trust: human biology,” said Shabana Sayed, Senior Embryologist and IVF Lab Manager at Klinikk Hausken.

“Its transparency and interpretability set it apart from other AI-based decision support tools available.”

Founded in 2019, Fairtility is based in Tel Aviv.